TITLE

GENMAB/IMMUNEX TO DISCOVER AND DEVELOP CANCER ANTIBODY

PUB. DATE
November 2001
SOURCE
Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents information on a collaborative agreement of Genmab A/S with Immunex Corporation to discover and develop an antibody against lymphoma as of November 2001.
ACCESSION #
5457846

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that Genmab A/S submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL).

  • Serono is investing in Genmab antibody.  // Chemical Market Reporter;8/22/2005, Vol. 268 Issue 6, p7 

    Reports on European biotechnology company Serono's plan to invest in Genmab AS as part of an agreement in which Serono gets exclusive worldwide rights to develop and commercialize Genmab's oncology monoclonal antibody, HuMax-CD4 (zanolimumab). Terms of the agreement; Development of the HuMax-CD4...

  • Sale of Genmab Shares Garners Medarex $151.8M.  // Bioworld Week;2/11/2008, Vol. 16 Issue 6, p2 

    The article reports on the expected sale of $151.8 million to Medarex Inc. in Princeton, New Jersey from the 2.5 million shares of Genmab AS, a firm in Denmark whose stock is traded on the Copenhagen Stock Exchange. The sale reduces Medarex's ownership in the Danish firm from about 11% to 5.1%....

  • Streamlining Genmab Cuts 100 Jobs, Drops Pivotal CTCL Drug. Boggs, Jennifer // BioWorld Today;10/9/2008, Vol. 19 Issue 197, p1 

    The article reports on the decision of Danish antibody firm Genmab A/S to cut about 15 percent of its work force and halt work on a Phase III program in cutaneous T-cell lymphoma (CTCL). According to Genmab chief executive officer (CEO) Lisa Drakeman, the moves were necessary as the company's...

  • Streamlining Genmab Cuts 100 Jobs, Drops Pivotal CTCL Drug. Boggs, Jennifer // BioWorld International;10/15/2008, Vol. 13 Issue 42, p4 

    The article reports on the decision of Danish antibody firm Genmab A/S to cut about 15 percent of its work force and halt work on a Phase III program in cutaneous T-cell lymphoma (CTCL). According to Genmab chief executive officer (CEO) Lisa Drakeman, the moves were necessary as the company's...

  • Ofatumumab Misses NHL Mark; Genmab Shares Take a Tumble. Sheridan, Cormac // BioWorld International;8/19/2009, Vol. 14 Issue 33, p1 

    The article reports on a decline in the value of shares of Genmab A/S following news that its anti-CD 20 antibody ofatumumab failed to show an objective response rate in non-Hodgkins lymphoma patents. The overall response rate was 10% in the high-dose section of the study while the overall...

  • Genmab's lymphoma treatment HuMax-CD4 receives fast track status from FDA.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p14 

    Reports that Genmab's HuMax-CD4 has been given a fast track designation by the U.S. Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have failed existing therapy. Significance of the fast track designation; Details of phase II clinical studies...

  • Genmab records positive HuMax-CD4 phase II lymphoma data.  // PharmaWatch: Cancer;June 2004, Vol. 3 Issue 6, p16 

    Reports on the positive results of Genmab's HuMax-CD4 phase II cutaneous T-cell lymphoma study. Significant dose response correlation in cancer patients participating in the study.

  • Genmab therapy achieves 55% response rate in lymphoma.  // PharmaWatch: Cancer;January 2005, Vol. 4 Issue 1, p7 

    Reports that Genmab AS's HuMax-CD20 has shown favorable clinical responses in a phase I/II trial, for the treatment of non-Hodgkin's lymphoma. Percentage of patients with relapsed or refractory follicular non-Hodgkin's lymphoma; Clinical response of patients in the 300 mg and 500 mg dose groups;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics